AstraZeneca’s mission in the cardiovascular therapy area is to increase lifespan and improve quality of life by reducing the risk, prevalence, and impact of cardiovascular and metabolic disease.

We are a world leader in CV medicines, backed by over 40 years experience. We aim to build on our strong position, focusing in the short to medium term on the growth segments of hypertension, dyslipidaemia, thrombosis and type 2 diabetes.

This site is intended for an international audience of healthcare professionals, providing information on our heritage, our products and our research and development programmes.